Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study

Date

21 Oct 2023

Session

Poster session 20

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Yuan-Kai Shi

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

Y. Shi1, Y. Zheng2, J. Chen3, X. Yu4, J. Fang5, Y. Liu1, D. Huang6, T. Liu7, H. Shen8, S. Luo9, H. Yu10, Y. Cao11, X. Zhang12

Author affiliations

  • 1 Department Of Medical Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, 100021 - Beijing/CN
  • 2 Department Of Oncology, The First Affiliated Hospital of Medical School of Zhejiang University, 310003 - Hangzhou/CN
  • 3 Thoracic Medicine Department I, Hunan Cancer Hospital, The Affiliated Cancer Hospitial of Xiangya School of Medicine, Central South University, 410013 - Changsha/CN
  • 4 Department Of Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 310022 - Hangzhou/CN
  • 5 Thoracic Oncology Second Department, Beijing Cancer Hospital, 100020 - Beijing/CN
  • 6 Department Of Thoracic Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, 300060 - Tianjin/CN
  • 7 Department Of Medical Oncology, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN
  • 8 Department Of Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, 310003 - Hangzhou/CN
  • 9 Department Of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 450003 - Zhengzhou/CN
  • 10 Department Of Radiation Oncology, The Affiliated Hospital of Qingdao University, 266021 - Qingdao/CN
  • 11 Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, 266021 - Qingdao/CN
  • 12 Department Of Clinical Research And Development, Shanghai Kechow Pharma, Inc., 210203 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1378P

Background

Addition of a MEK inhibitor to a BRAF inhibitor enhances tumour growth inhibition, delays acquired resistance of the MAPK pathway in BRAF V600-mutated cancers. We assessed the safety and efficacy of tunlametinib (HL-085), a novel highly selective MEK1/2 inhibitor, in combination with vemurafenib in patients(pts) with advanced BRAF-mutated solid tumors.

Methods

In this phase I study, pts with advanced solid tumors who had progressed on or shown intolerance to standard treatment were enrolled and received escalating doses of tunlametinib combined with vemurafenib in dose-escalation phase (followed a 3 + 3 design). Patients received tunlametinib at dose levels of 0.5, 6, 9, 12, and 15 mg BID, together with vemurafenib 960 mg BID, in 21-day cycles. In dose-expansion phase, tunlametinib 12mg + vemurafenib 960mg, tunlametinib 12mg + vemurafenib 720mg and tunlametinib 9mg + vemurafenib 720mg dose groups were evaluated. The tunlametinib 9mg + vemurafenib 720mg was determined as the recommended phase 2 dose (RP2D).

Results

As of the data cut-off date on 04, Nov, 2022, a total of 72 pts with solid tumors were enrolled. The most common AE were CK elevation, anemia and rash which were predominantly grade 1/2. 33 pts with non-small cell lung cancer (NSCLC) have been evaluated for response. The objective response rate (ORR) was 60.6% (95%CI: 42.1%, 77.1%), a median duration of response (DoR) was 11.3 months (95% CI: 3.9, NE), and a median progression free survival (PFS) was 11.7 months (95% CI: 5.6, NE) . At the RP2D, ORR was 60.0% (95%CI: 32.3%, 83.7%) and mPFS was 10.4 months (95% CI: 5.6, NE). 24 pts with metastatic colorectal cancer (mCRC) at all doses, ORR was 25.0% (95%CI: 9.8%, 46.7%), mDoR was 5.5 months (95% CI: 2.9, NE), and mPFS was 6.2 months (95% CI: 4.8, 7.6). Antitumor activity was also seen in papillary thyroid carcinoma and pancreatic ductal adenocarcinoma.

Conclusions

Tunlametinib in combination with vemurafenib showed promising antitumor activity and manageable safety profile in pts with BRAF V600-mutated solid tumors. Further studies are ongoing.

Clinical trial identification

NCT03781219.

Editorial acknowledgement

Legal entity responsible for the study

Shanghai Kechow Pharma, Inc.

Funding

Shanghai Kechow Pharma, Inc.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.